|Previous Section||Index||Home Page|
The Minister of State, Department of Health (Jacqui Smith): I commend the hon. Member for Richmond Park (Dr. Tonge) on securing this Adjournment debate. I welcome the debate, and her obvious expertise. As she rightly says, it is always a pleasure to talk about health issues. The debate gives the Government an opportunity to state clearly our policy on the treatment of respiratory
The range of respiratory diseases that people can suffer from is very wide, and it would be impossible for me to talk about what the Government are doing in respect of them all in such a short debate, although it is slightly longer than we had presumed. I will concentrate in the time available on a few of the major conditions such as lung cancer, asthma, pneumonia and chronic obstructive pulmonary disease. I shall also refer to tuberculosis, which the hon. Lady mentioned.
The hon. Lady suggestedI think wronglythat the Government's concentration on specific clinical areas had led in some way to a downgrading of the importance of respiratory disease. It is important to spell out that existing programmes have supported action on chest disease. The existing programmes for action on coronary heart disease will lead to improvements in the treatment of respiratory disease, because one of the key risk factors for coronary heart disease is cigarette smoking. It is the key cause of fatal lung diseases, such as lung cancer and chronic bronchitis, and increases the risk of pneumonia. I will refer more to smoking later.
Furthermore, many respiratory conditions are more prevalent in older people. The work being undertaken on the implementation of the national service framework for older peopleaddressing ageism, the development of a single assessment process and improved access to specialist care in hospitalswill produce improvements in access, prevention, treatment and services for all older people.
The hon. Lady highlighted lung cancer, which is the second most common cancer in England. In April 2001, the Government launched phase 2 of the cancer services collaborative programme, which is already producing some good examples of demonstrable reductions in waiting times for lung cancer treatment. Clearly, we would expect to see significant further progress.
An additional £10 million has been made available each year from 1999 to develop lung cancer services and is being used to help improve access to those services, to enhance the quality of treatment and to bring down waiting times for treatment for lung cancer.
We have asked the National Institute for Clinical Excellence to prepare clinical guidelines on the diagnosis and treatment of lung cancer to supplement the existing service guidance published by the Department of Health in 1998. It is likely that those guidelines will be published in autumn 2003. NICE, in June 2001, published appraisals of the various new generation chemotherapy drugs for lung cancer. We estimate that up to 5,000 patients will benefit from having those drugs available.
The hon. Lady spoke about pneumonia. Many deaths, including deaths from pneumonia, can be prevented by influenza immunisation, which is why the chief medical officer launched the flu vaccination campaign. We are pleased that take-up improved again this year, with 68 per cent. of older people getting vaccinated, compared with
Eighty per cent. of patients with community-acquired pneumonia are managed by general practitioners, but most of the NHS costs of pneumonia treatment, amounting to more than £400 million a year, are associated with hospital admission. Prompt treatment in the community could reduce NHS costs and patient morbidity by reducing both the need for hospital admission and the length of hospital stay. Government investment and action in increasing capacity for treatment and the extent to which community and primary care can deal with those diseases is therefore crucial.
Dr. Tonge: I appreciate what the Minister has said about pneumonia, particularly in elderly people. In fact, in the old days it used to be called the old man's friend; it is often a terminal event in many illnesses. However, I must take the Minister up on her claim that the Government have been concentrating on funding primary care trusts and bodies outside hospitals to keep elderly people out of hospital. I do not want to go into the problem of bed blocking and the loss of nursing home places in this debate, but the Department may not appreciate that there is simply not enough community care for elderly people or anybody else. There are just not the bodies, spaces, beds or homes, to care for those people.
Jacqui Smith: That is why our action supporting social services and our success in cutting delayed discharges are important. The development of intermediate care services, particularly services which can respond quickly to the needs of older people with respiratory diseases who remain in their homes, will lead to further progress in ensuring that we catch some of those infections earlier and prevent hospital admission. In that way, we can improve the way in which the whole system works and, most importantly, improve older people's experience of care. Many local authorities and health authorities are using the increased investment that the Government are making available for intermediate care for precisely that sort of rapid response and care in people's homes.
Dr. Tonge: I feel passionately about this. Having been in health service management and administration myself, I know that one can often think that things are happening on the ground when they are not. I assure the Minister that there is not much evidence to suggest that such improvements are happening there. As she is suggesting that intermediate care is progressing and that a lot of facilities are being opened up, will she and her
Jacqui Smith: I would be very happy to do so. I have visited such places and I am willing to write to the hon. Lady about the progress that we are making in delivering on our pledges in relation to intermediate care.
The hon. Lady also referred to chronic obstructive pulmonary disease. As she pointed out, such disease leads to approximately 20,000 deaths each year. It also causes about 90 per cent. of respiratory disability. Expert groups working internationally have developed clinical guidelines for the treatment of COPD, which is shared between general practitioners and hospital doctors. Increasingly, COPD is being managed like other chronic diseases, with skilled teams offering lifelong care and often pulmonary rehabilitation to improve very significantly the quality of life of people with the disease. We have also asked NICE to prepare clinical guidelines for the NHS in England and Wales on the prevention, diagnosis, management and treatment of chronic obstructive pulmonary disease. Development work is currently under way on those guidelines.
As the hon. Lady pointed out, and as I said earlier, smoking is the cause of many serious respiratory diseases. It is the major cause of lung cancer and COPD and almost doubles the risk of pneumonia. That is why our anti-smoking initiatives are so important. Reducing the burden of avoidable disease will be good for the patient, good for the NHS and good for the nation. I am pleased to say that the United Kingdom is now a world leader in smoking cessation.
In the four years to 2003, we have allocated £73 million to the NHS to provide a national NHS smoking cessation service. Excellent results are already being achieved. The results for the first full year of the service, from April 2000 to March 2001, showed that about 132,500 people had set a quit date, with some 64,600 people successfully having quit at the four-week follow-up stage. We have also made smoking cessation aids available on NHS prescription. Zyban was made available in June 2000 and nicotine replacement therapy was made available in April 2001. Substantial resources have been made available to the NHS for this purpose. In addition, almost all NRT products are now available on general retail sale.
Jacqui Smith: I was just coming to that bit of my speech, although I am certainly willing to add to my letter on intermediate care some more details about progress with young women and smoking. An important element of the overall tobacco strategy is the health education programme, to which some £55 million has been allocated in the period 19992000 to 200203. The programme involves a mass media advertising campaign that is designed to address the 25-to-45 age group and the development of separate approaches in relation to pregnant women.
The hon. Lady pointed out that the private Member's Bill on banning tobacco advertising has been discussed today on Third Reading in another place. The Bill has been supported by Ministers in the other place. The Government are committed to legislating on tobacco advertising during the current Parliament, but of course the fate of legislation that originates in the other House is not for me to decide. Progress will depend on the House authorities and the extent to which parliamentary time is available. It remains an objective of the Government to legislate on tobacco advertising and as I have demonstrated, we have taken significant action to reduce smoking because of its considerable contribution to ill health.
The hon. Lady mentioned asthma. Although asthma prevalence has increased in England, as in western Europe, asthma deaths are falling, almost certainly as a result of better management. I was a little disappointed with the hon. Lady. I know that she was calling for both increased investment and increased emphasis on respiratory diseases, but I do not support the view that she seemed to be advancing at various times that everything in the health service relating to chest diseases is poor or substandard.
Much excellent work is clearly being done in our health service on a wide range of chest diseases by extremely dedicated staff, which will be supported further by the extra investment and reform that the Government are putting in place. Asthma is one area in which better management has been important in reducing deaths.
We are aware that the treatment of asthma can be improved. Our report into the expert patient provided evidence that self-management in asthma could reduce the number of attacks and improve lung function. Professionals can also help people manage their asthma attacks through written plans on managing their asthma and regular reviews.
The hon. Lady raised the important subject of the work force. We recognise that treatment of respiratory disease is a high-priority specialised area. In 1997 there were 109 specialist registrars in respiratory medicine. That figure has increased year on year and by 2001 had reached 257, which represents a significant increase. In 1997 there were 104 specialist registrars in cardiothoracic surgery. By 2001 that figure had risen to 199, an increase approaching 100 per cent. Our projections show that from a September 2000 baseline of 198, numbers should increase to 223 by September 2004.
I agree with the hon. Lady that the previous Government left us a considerable challenge to increase work force numbers. We will continually review future work force needs as part of our national work force planning processes and take action to address any shortfalls. In the longer term, our current supply
The hon. Lady highlighted the issue of tuberculosis. There is, regrettably, an international resurgence of the disease. We need to be aware of that and take appropriate action. We recently announced plans for a new national infection control and health protection agency to streamline the services involved in the prevention and control of infectious diseases. The new agency will provide an integrated approach to all aspects of health protection, as well as infectious disease control. That will have an impact on infectious chest diseases such as tuberculosis and influenza.
The hon. Lady is right in her assertion that poverty is an important contributory factor in many respiratory diseases. As with many areas of policy, the significant actions taken across government to tackle povertyfor
I hope that the hon. Lady will accept, if not agree with me, that the Government take the treatment of chest disease extremely seriously. We are investing considerable sums into improving lung cancer services. Our expenditure on anti-smoking initiatives will have an impact on the diseases caused by smoking. We are supporting, through the Medical Research Council, research into a wide range of respiratory diseases. We are asking NICE to develop guidelines for lung cancer and COPD. We are taking steps to increase the number of consultants who are available to treat people with lung disease, and we have recently launched a new strategy for dealing with infectious diseases.
I am pleased that we have had the opportunity to address the issue, not least because it enables us to show that the Government take the matter extremely seriously. Along with other initiatives, increased investment in the health service, and reform, have delivered, and will continue to deliver, important results.